Adjuvant chemotherapy and survival among patients 70 years of age and younger with node-negative breast cancer and the 21-gene recurrence score of 26–30

BACKGROUND: The benefits of chemotherapy in node-negative, hormone receptor-positive, and human epidermal growth factor receptor 2 (HER2)-negative breast cancer patients with the 21-gene recurrence score (RS) of 18–30, particularly those with RS 26–30, are not known. METHODS: Using the Surveillance,...

Descripción completa

Detalles Bibliográficos
Autores principales: Park, Seho, Han, Yunan, Liu, Ying, Toriola, Adetunji T., Peterson, Lindsay L., Colditz, Graham A., Kim, Seung Il, Cho, Young Up, Park, Byeong-Woo, Park, Yikyung
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6796491/
https://www.ncbi.nlm.nih.gov/pubmed/31619259
http://dx.doi.org/10.1186/s13058-019-1190-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6796491/
https://www.ncbi.nlm.nih.gov/pubmed/31619259
http://dx.doi.org/10.1186/s13058-019-1190-4

Ejemplares similares